220 , e202009045 (2021)
Although GLP-1RA and SGLT-2i combination therapy is associated with a higher risk for some adverse events, such as hypoglycaemia and injection-site-related events, no severe adverse events were found
METHODS We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition
According to the complaint, consumers were led to believe the compounded injections were equivalent to the branded drugs, when in fact they allegedly contained additional ingredients and were produced through a different process
Tambin observamos cambios positivos en nuestro metabolismo general
(4) Department of Physiology and Pharmacology Vittorio Erspamer, Sapienza University of Rome, Italy